The current price of PHR is $12.62 — it has decreased by 0.71% since the previous close. Data as of Nov 6, 2026.
PHR is up 1.37% over the past week, up 20.19% over the past month and down 42.69% over the past year. The price is above its 200-day moving average of $10.86.
Analysts' average 12-month price target for PHR is $12.14, which implies 3.80% downside from the current price. Individual estimates range from $10.00 to $16.00.
Of the 18 analysts covering Phreesia, Inc., 2 rate it a strong buy, 8 rate it a buy and 8 rate it a hold. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.
Phreesia, Inc. has a market capitalization of $783.33M. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, Phreesia, Inc. posted earnings of $0.03 per share against an estimate of $0.08506, missing expectations by 64.73%. Upcoming reports are listed in the earnings calendar.
Phreesia, Inc. reported revenue of $129.46M in its most recent quarter, which has increased by 10.41% compared with the same quarter a year earlier. Analysts had expected $129.06M.
Phreesia, Inc. has not paid any dividends over the past year.
Companies most comparable to Phreesia, Inc. include Neogen Corporation, Schrödinger, Inc., Establishment Labs Holdings Inc., BioLife Solutions, Inc. and Kestra Medical Technologies, Ltd.
In the latest trading session PHR moved between $12.27 and $12.64, a range of 2.94% of its current price.
Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Phreesia, Inc. shows a buy rating today and a buy rating on the weekly timeframe. Market conditions change quickly, so it is worth looking further ahead as well — the 1-month rating for Phreesia, Inc. is sell. Technical ratings are indicators, not investment advice.
Over the past 52 weeks PHR has traded between $7.77 and $23.31. The current price is 45.86% below its 52-week high.
Figures as of Nov 6, 2026. This information is provided for general purposes only and is not investment advice.